Combination treatment of fingolimod with antidepressants in relapsing–remitting multiple sclerosis patients with depression: a multicentre, open-label study – REGAIN

ePoster Session 1

(2015)   Multiple Sclerosis Journal

ePoster Session 1

(2015)   Multiple Sclerosis Journal

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors

(2015) R.A. Bermel et al.   Multiple Sclerosis and Related Disorders

Meta-Analysis of Selective Serotonin Reuptake Inhibitor–Associated QTc Prolongation

(2014) Scott R. Beach et al.   JOURNAL OF CLINICAL PSYCHIATRY

Pathogenic Mechanisms of Depression in Multiple Sclerosis

(2014) Joe John Vattakatuchery et al.   JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

(2014) Edward Fox et al.   Multiple Sclerosis and Related Disorders

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

(2014) John P. DiMarco et al.   Multiple Sclerosis and Related Disorders

Duloxetine Is Effective in Treating Depression in Multiple Sclerosis Patients

(2013) Claudio Solaro et al.   CLINICAL NEUROPHARMACOLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of escitalopram on stress-related relapses in women with multiple sclerosis: An open-label, randomized, controlled, one-year follow-up study

(2009) Charalampos I. Mitsonis et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications

(2009) Murtuza Bharmal et al.   Health and Quality of Life Outcomes

Multiple sclerosis beyond EDSS: depression and fatigue

(2009) Tjalf Ziemssen   JOURNAL OF THE NEUROLOGICAL SCIENCES

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

(2009) G. Comi et al.   Multiple Sclerosis Journal

The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)

(2009) LC Doward et al.   Multiple Sclerosis Journal

Depression and anxiety amongst multiple sclerosis patients

(2008) A. G. Beiske et al.   EUROPEAN JOURNAL OF NEUROLOGY

Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis

(2008) Dawn M. Ehde et al.   GENERAL HOSPITAL PSYCHIATRY

Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study

(2008) J P Mostert et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY